COX-2 expression in tumour cells has been associated with carcinogenesis in many human neoplasms, including head and neck cancer, while the COX-l isoform of the cyclooxygenase enzyme is constitutively expressed in normal tissues. We measured COX-l and COX-2 m-RNA expression in samples of both oral cancer and matched oral mucosa from 22 patients by RealTime RT-PCR; clinic pathological data (grading, TNM staging, inflammation, follow-up) of all patients were available for statistical evaluation. Most of the tumor samples in our study expressed at least one cyclooxygenase enzyme (COX-lor COX-2 mRNA) more than their matched normal oral mucosa (p<O.05), with no correlation with the entity of inflammation, and a significant inverse relationship was found between COX-l and COX-2 in each sample. Higher levels of COX-2 expression were associated with poor disease-free survival (p<O.05), but not with overall survival and higher tumor stage and grade. Our results suggest that COX-l may playa role in oral carcinogenesis, and could be regarded as a potential therapeutic target by chemo preventive drugs; moreover, COX-2 expression might be addressed as a new prognostic tool in the clinical management of OSCC.
(COX), a key enzyme in conversion of arachidonic acid to prostaglandin, may be involved in the pathobiology of human oral carcinogenesis. COX has two isoforms, namely COX-I and COX-2. Traditionally, COX-I has been considered a "housekeeping enzyme" constitutively produced in several tissues under normal physical conditions, whereas COX-2 is induced by pathological stimuli, such as inflammation, growth factors and cytokines produced by tumour cells. In particular, abnormal expression ofCOX-2 has been supposed to be related to the pathogenesis of human cancer by affecting cell proliferation and apoptosis, angiogenesis and immune surveillance against cancer (2) . On the basis of such molecular findings, more recent in vitro and epidemiologic studies focus on the putative role of non-steroidal anti-inflammatory drugs (NSAIDs), and in particular COX-2 inhibitors, as more selective and side-effect free anti-neoplastic, or even chemopreventive, agents (3) (4) (5) .
The aim of this RealTime RT-PCR study is to evaluate COX-I and COX-2 mRNA content in 44 tissue samples (22 tumour samples and 22 normal mucosa) obtained from patients affected by oral squamous cell carcinoma (OSCC) and to correlate molecular with clinic pathological findings.
MATERIALS AND METHODS

Selection ofcases
Cases were randomly selected from the files ofpatients who underwent excision of oral squamous cel1 carcinoma in the Department of Surgery, University ofAncona, Italy, between 1999 and 2001. Twenty-two cases (12 men and 10 women, see Table I ), fulfil1ed the requirement; thus, paired tissue specimens of cancer tissue and normal oral mucosa were included into this study. The tumour stage was assessed according to the 2000 International Union Against Cancer (UICC) TNM classification of malignant tumours; the histopathological grading of tumours and the morphological characteristics of inflammatory cel1s were determined on paraffin H-and E-stained sections.
Al1 specimens were obtained from each patient during surgery, fol1owing a protocol that was reviewed and approved by the ethical review boards of our Institutions. Patients had not previously been treated or received surgical treatment; in al1 cases a 2 to 4-year fol1ow-upwas available. Each resected specimen was quickly divided in two parts. From one of these parts, formalin-fixed paraffin-embedded serial sections were obtained to be used for H&E and IHe. The other part was immediately deep frozen and stored at -80°C for RT-Real Time PCR analysis.
RNA extraction
Twenty 40 mg specimens of deep-frozen tissue were used for total RNA extraction. Total RNA was isolated by using guanidinium thiocyanate, as described by Chomczynski et al. (6) ; the integrity ofal1 tested total RNA samples was verified by agarose gel electrophoresis.
Reverse transcription
Samples containing 5 Jig of total RNA in a final volume of 100 JiL were reversed-transcribed by avian myeloblastosis virus (AMV) reverse transcriptase (Promega, Madison, WI), according to the manufacturer's instructions. Random hexamer primers were used, and the reaction was incubated for 60 min at 42°e. The ss-cDNA obtained was used for Real-Time PCR amplification.
Real-Time peR
Real-Time-PCR analysis of COX-I and COX-2 gene expression was performed by using the iCycler® apparatus (BioRad) with sequence-specific primer pairs for the genes tested. The housekeeping gene glyceraldehyde-phosphate-dehydrogenase (GAPD H) was used as internal control. The primers used were the fol1owing: GAPDH forward (5'-TTG GTA TCG TGG AAG GAC TCA -3') and reverse (5' -TGT CAT CAT ATT TGG CAG GTT T -3'); COX-l forward (5' -GCAGCTGAGTGGCTATTTCC -3'), and reverse (5' -TGCCAGTGGTAGAGATGGTT -3'); COX-2 forward (5' -GCCATCTTTGGTGAAACCAT -3') and reverse (5' -TTGAAAACCCACTTCTCCAC -3').
The cDNA was serial1y diluted and every dilution was run in triplicate. The Real-Time PCR analysis was performed as fol1ows: initial denaturation step: 95°C for 3 min fol1owed by 50 cycles of denaturation at 95°C for 1 sec; annealing: 10 sec at 50°C; elongation: 8 sec at n°e. The IQ Sybr Green SuperMix (BioRad) was used for real time monitoring of amplification. In brief, amplification was performed in a total volume of 20 Ill. The reaction mix was performed with 10 III of 2x IQ Sybr Green SuperMix, 0.5 III of each primer 16 11M and 2 III of cDNA (or water as blank, which was always included). The real-time PCR products were run on 2% agarose gel containing TAE (standard Tris-Acetate-EDTA electrophoretic buffer). The amplicons of expected size were extracted, purified and control1ed for sequences by Biogem DNA Sequencing Core (Biogem, Naples).
Results were evaluated by ICYCLER IQ Real Time Detection System Software® (BioRad, Hercules, Ca). Data were calculated based on threshold cycle (Ct), which represents the early phase of the logarithmic amplification and is determined as the cycle having a signal higher than background (signal detected at cycles 2-10) plus 10 times its standard deviation. The Ct value at which the PCR exponential reaction starts is inversely proportional to mRNA levels and differences in Ct values (LlCt) reflect differences in mRNA copy number.
The number of times the mRNA level of a sample n l is higher or lower than that of a sample n 2 is, in general, equal to 2"c,. The expression ofthe analyzed genes was first normalized with respect to GAPDH transcript level and then the value corresponding to each pathological sample was compared with its specific relative normal mucosa counterpart. The observed difference was expressed as 2"Ct (pathological/normal mucosa gene expression ratio, as evaluated by mRNA analysis).
Statistical analysis
The data were analyzed by the Stanton Glantz statistical software 3 (MS-DOS) and GraphPad Prism4. Differences between the groups were determined using the one-way analysis of variance (ANOVA) and the Student-Newman-Keuls test. Pearson's method was used to study linear correlation and to determine the relationship among gene expression and the degree of inflammation; finally, the Kaplan-Meier test was used to examine the effect of COX-I and COX-2 expression in relation to overall and disease-free survival. A P-value less than 0.05 was considered to be statistically significant.
RESULTS
Findings on quantitative expression of cyclooxygenase isozymes as evaluated by Real-Time RT-PCR are shown in Table II We analytically studied the correlation of molecular data with clinic and pathological variables and we obtained the results shown in Fig. 2 . Briefly, a statistical correlation was found between COX-2 overexpression and disease-free survival (p<0.05), but not with overall survival (p>0.05). Moreover, both COX-I and COX-2 m-RNA expression assessed by Real-Time RT-PCR were unrelated to the presence of intratumorallymphocytic infiltration and peritumoral inflammation assessed by light microscopy examination of ematoxylin-eosin slides on a semi-quantitative score (Pearson's test COX-I, r = 0.43; COX-2, r = 0.15).
We demonstrated a significant negative correlation between patient disease-free survival and COX-2, but not COX-I, expression (p<0.05); no correlation was detected with overall survival, tumour stage and grade. Furthermore, we showed a possible site-specific expression pattern of COX-I and COX-2 in OSCC. As shown in Table I , we could recognize at least two specific regions of cancer sites; 7 out of 22 patients have cancer in gingiva, II patients have cancer in the tongue, and 4 patients have cancer in different sites including mouth floor, cheek, and trigonous areas. In this study we show that 85% of patients with gingival cancer over-expressed COX-2, but not COX-I (6 out 7 patients) (see Table I and Fig. I ). Furthermore, 55% of the patients with cancer of the tongue over-expressed COX-2 (6 out of II patients); interestingly, none of the patients with gingival cancer over-expressed COX-I, but gingival cancer rather showed a trend to a general down-regulation of COX-I. However, our observations on sitespecific expression patterns of COX-2 and COX-I in OSCC need to be validated by further study on a wider series of patients. With regard to other clinicpathological characteristics, we could state that levels of COX-I and COX-2 expression were not statistically associated with tumor TNM staging and pathological grading.
DISCUSSION
The starting point of this study was our previous observation of COX-2 isozyme over-expression in OSCC (2) . Interestingly, in a previous work we found over-expression of COX-I in a small series ofOSCC both at mRNA and at protein level, as analysed by Real Time RT PCR and immunohistochemistry respectively (data not shown). Such unexpected results and the few most recent works on COX-l in human cancer elicit the following questions: which is the role of COX-l in OSCC? Are COX-l and COX-2 over-expressed together or alternatively in these tumors? Thus, we decided to use highly specific and sensitive Real Time-PCR technique in order to determine the levels of both cyclooxygenase isozymes in each case of OSCe.
Twenty out of twenty-two tumor samples expressed at least one cyclooxygenase enzyme (COX-lor COX-2 mRNA) more than their matched normal oral tissue; it was noteworthy that in this study over-expression of COX-I, but not COX-2, was found to be statistically significant on ANOVA and Student-Newman Keuls test (p<0.05) (Table II) . Such findings are in keeping with recent studies by immunohistochemistry, which demonstrate staining of COX-l in thyroid tumors but not in normal thyroid tissue (7) ; over expression of COX-l was also found in ovarian (8) and cervical cancer (9) (10) . Also, experiments on murine models of cancer underline that both isoforms are involved in the development of skin cancer (11). Moreover, in a most recent review on the immunosuppressive role of COX-inhibitors on tumor cells, Lang et al (12) stated that high expression levels of at least one of the two COX enzyme are detectable in human cancers. Taken together, such data seem to suggest that this enzyme, which has long been considered the constitutive isoform of cyclooxygenase, physiologically expressed in normal tissues, may play a more relevant role in the development of tumors than expected, most likely by modulating gene expression and promoting neo-angiogenesis via autocrine/paracrine regulation of vascular growth factors (13) (14) .
A significant inverse relationship was found between the two cyclooxygenase isoforms, which to our knowledge has never been reported in literature (Fig. I) . It would be tempting to speculate on the biochemical implications of such finding; however no definitive conclusions can be made due to the small number of cases analyzed in our study, and to the small amount of papers addressing the analysis of both COX-l and COX-2 in tumour samples.
OSCC are commonly associated with massive inflammation which can be regarded as a host 'immune' reaction to tumor antigens as well as the consequence of its peculiar site, though there is rising evidence that inflammation might be a crucial event in the pathogenesis of this tumor (15) ; moreover, COX-I is commonly present in sites of inflammation due to its key role in prostaglandin biosynthesis. Thus, we decided to assess the inflammation rate of each tumor sample at light microscopy on a semi-quantitative score. We found no statistical correlation between both COX-I and COX-2 over-expression and the presence of intratumoral lymphocytic infiltration and! or flogistic infiltration beneath the tumor on Pearson's test, which would suggest that the up-regulation of the two isoforms is not only related to inflammatory stimulation. Furthermore, we could observe that higher quantitative (number of stained cells) and qualitative (intensity of staining) COX-I and COX-2 staining is detected in tumor cells as well as in inflammatory cells by immunohistochemistry (data not shown).
The current study showed the lack of any association of COX-2 over-expression as assessed by immunohistochemistry with VICC TNM stage and tumor differentiation, while high levels of COX-2 mRNA were significantly associated with patient disease-free survival, but not overall survival on Kaplan-Meier test (Fig. 2) . Such findings are most in keeping with those by Itoh et al (16) who analysed a larger group of patients by immunohistochemistry. This raises the possibility that COX-2 could impact on disease-free survival (i.e. development of loco-regional relapses and distant metastases) through mechanisms other than tumour stage; moreover, assessment of COX-2 status, either by immunohistochemistry or by molecular techniques, might be regarded as an independent prognostic factor in OSCC, as has been suggested in oesophageal adenocarcinoma (17) .
Many in vitro studies and clinical trials have recently confirmed the efficacy of non-steroidal anti-inflammatory drugs in anticancer therapy, most of them addressing the potential efficacy of COX-2 inhibitors in comparison to traditional nonselective agents (18) . As for OSCC therapy, only few conflicting data are available in literature on these drugs as chemo-preventive agents, since their real protective effect has not yet been entirely proven (4) . Even less is known about the antineoplastic role of molecules which specifically address the COX-I isoform; in a large in vitro study on human colorectal cancer cells, Bottone et al (13) found that SC-560, a COX-I selective inhibitor was a more powerful apoptosis inductor than a COX-2 inhibitor on cancer cell lines; both act probably through gene expression modulation, though the underlying mechanisms are not completely understood.
So far, very little is known about the putative role of the COX-I compared to the COX-2 isoform of the cyclooxygenase enzyme in human carcinogenesis; our findings of COX-I significant over-expression in OSCC than normal oral mucosa are consistent with several recent lines ofevidence suggesting that COX-I may playa causal role in tumour development through gene interaction and neo-vascularisation. This must be taken into account in the design of in vitro and clinical trials on selective chemopreventive and chemo-therapeutic drugs, since there is increasing evidence that the use of COX-I and non-selective inhibitors could be effective in cancer treatment (12) .
Our data, in keeping with findings from previous larger studies, seem to support the prognostic relevance of COX-2 expression in OSCC; further studies are therefore needed in order to assess whether the assessment of COX-2 expression may be included among the prognostic indicators in clinical practice of OSCe.
